WO1996032191A1 - Microencapsulation process - Google Patents
Microencapsulation process Download PDFInfo
- Publication number
- WO1996032191A1 WO1996032191A1 PCT/US1996/003731 US9603731W WO9632191A1 WO 1996032191 A1 WO1996032191 A1 WO 1996032191A1 US 9603731 W US9603731 W US 9603731W WO 9632191 A1 WO9632191 A1 WO 9632191A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gelatin
- emulsion
- microcapsules
- oil
- microencapsulation
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
Definitions
- MICRQENGftPSU ftTIQN PROCESS This application relates to a process for microencapsulation of various materials and more particularly to such encapsulation by means of coacervation techniques.
- microencapsulation employ polyamino acids in conjunction with other polymers to form or aid in forming microcapsules. Examples are shown in U.S. 4,990,336 and 5,126,147 to Silvestri, et al. which provide biodegradable microcapsules for sustained release medications. Polypeptides are formed from esterified polyamino acids to form polymers which, upon precipitation form microspheres containing diverse biological agents. Polyamino acids have also been employed to provide surface coatings for medicinal purposes and foods for ingestion by animals and humans. Typically polysuccinimide or derivatives thereof are dissolved in a suitable solvent and the material to be coated is contacted with the solution of the polymer and dried. Examples of this type of operation are found in U.S.
- Polypeptides are capable of being tailored by forming copolymers. Esterified polyaspartic and polyglutamic acids are taught as microencapsulation polymers which are also modified by the type of ester group to control degradation. Such controlled degradation is especially useful in providing drug treatment. Microcapsules of this type comprise a polymeric membrane and contain an aqueous or oily solution in which the drug is suspended or dissolved. The drug is progressively released as a result of biodegradation of the polypeptide polymer.
- microcapsules are disclosed in U.S. Patent 4,803,168 to Jarvis wherein viable cell- containing microcapsules are formed from polyanionic polymers such as polyaspartic acid or polyglutamic acid and chitosan. These microcapsules are comprised of an inner layer comprising chitosan and an outer layer comprising the polyanionic polymer. These layers become cross-linked between the cationic amine groups on the chitosan and the anionic groups on the polyanionic polymer to form a water-insoluble permanent capsule. Such microcapsules are capable of retaining in their interior viable cells which can grow and reproduce.
- polyanionic polymers such as polyaspartic acid or polyglutamic acid and chitosan.
- These microcapsules are comprised of an inner layer comprising chitosan and an outer layer comprising the polyanionic polymer. These layers become cross-linked between the cationic amine groups on the chitosan and the anionic groups on the polyanionic polymer to form
- the wall around the core is hardened by several means such as by the addition of formaldehyde or glutaraldehyde.
- the suspension of microcapsules is cooled and the pH raised after which the suspension is filtered leaving the microcapsules on the filter media.
- Complex coacervation is employed to encapsulate solids and liquids. Further explanation of complex coacervation techniques is discussed in the Encyclopedia of Chemical Technology, Third Edition, Vol. 15, pp. 470-493, published by John Wiley & Sons, N.Y., N.Y, which is hereby incorporated by reference.
- Gum Arabic is also known as Acacia, a plant exudate.
- microencapsulation In the art of microencapsulation, the problems encountered involve the production of microcapsules in which only a certain percentage of those formed successfully encapsulate a liquid core without leaking. The production of a percentage of microcapsules that leak reduces efficiency and wastes product.
- gelatin is an available material for microencapsulation, it is given to degradation with concomitant odor of ammonia being exuded. While gelatin is relatively inexpensive such problems have limited its use in microencapsulation to preparing temporary microcapsules.
- microencapsulation process which could utilize microencapsulation gelatin to prepare permanent microcapsules with high efficiency.
- One of the most practical ways to increase efficiency of any microencapsulation process is to produce a high percentage of non-leaking microcapsules.
- microencapsulation process which employs gelatin and polyaspartic acid as coacervates which provides highly advantageous non-permeable microcapsules.
- the microcapsules prepared by the process of this invention are uniformly spherical and the novel process substantially completely microencapsulates all actives employed in the process. Also surprisingly, there is provided in accordance with this invention the substantial elimination of microcapsules which allow active material to escape prematurely.
- gelatin is employed in a complex coacervation process to encapsulate any number of active materials wherein polyaspatic acid or salt thereof is provided as the second marcomolecule (anionic agent) which allows the gelatin to form around the active agent being encapsulated.
- the capsule walls are then cross linked by typical prior art means such as reaction with an aldehyde, commonly glutaraldehyde. It has been found that stable, non-leaking spherical microcapsules are obtained which are of substantially uniform microencapsulation.
- Fig. 1 is a flow diagram of typical complex coacervation process for microencapsulation.
- Figs. 2 and 3 are photo micrographs of typical microcapsules produced in the process of this invention.
- FIG. 1 A typical flow diagram for complex coacervation as shown in Fig. 1 generally describes the process of this invention.
- the polyanion shown in the complex coacervation step is, in accordance with this invention, polyaspartic acid or a salt thereof.
- polyaspartic acid or a salt thereof typically an alkali metal salt of polyaspartic acid or the acid itself is employed.
- the polyaspartic acid or salt thereof is typically obtained by means of thermal condensation of aspartic acid, preferably 1-aspartic acid.
- polyaspartic acid provides the coacervate of this invention.
- Polyaspartic acids of various molecular weights can be employed in the process of this invention. Most processes provide polyaspartic acid polymers having molecular weights in the range of from about 5,000 to about 12,000. However, higher molecular weight polymers may be employed ranging up to 20,000, without exceptional modification of the process. Any water soluble polyaspartic acid is useful in the process of this invention.
- Gelatin of many types and grades can be employed to encapsulate active material in accordance with this invention.
- Typical gelatins include Type A of from 100 to about 300 Bloom as well as Type G gelatin (ossein) typically of from about 200 to about 300 Bloom.
- Gelatin is described in The Encyclopedia of Chemical Technology referred to above at Vol. 12, pp. 406-416 which is hereby incorporated by reference.
- any number of active materials which can be suitably suspended or emulsified in an emulsion can be employed in the process of this invention.
- Typical active materials are listed in the Encyclopedia of Chemical Technology, Vol. 12 and Vol. 15 noted above.
- Any water insoluble liquid or solid which can be emulsified in an aqueous solution of gelatin at convenient temperatures such as in the range of from about 45°C to about 60°C may be encapsulated in accordance with this invention.
- active material include dyes or dye intermediates for carbonless copy paper, usually crystal violet, food products, photographic materials, flavors and essences, pesticides and herbicides, adhesives, visual indicators and pharmaceuticals.
- the process of this invention involves in the first steps, the dissolving of gelatin in a suitable solvent, usually water.
- a suitable solvent usually water.
- the gelatin solution is then combined with the active material which, in Fig. 1, is described as an oil.
- An oil-in-water emulsion is formed with agitation and the temperature is held mildly elevated in the range of about 50°C.
- polyaspartic acid or salt thereof is added which provides ions of opposite electric charge than the gelatin.
- the emulsion is then subjected to conditions whereby complex coacervation of the gelatin occurs. This may be done by addition of an acid to adjust the pH of the emulsion or by adding sufficient water or both.
- the pH is adjusted to the range of from about 4.0 to about 4.5 with a weak acid such as glacial acetic acid.
- a weak acid such as glacial acetic acid.
- the gelatin forms microcapsules and provides walls around the material to be encapsulated.
- the emulsion is cooled to a temperature in the range of from 5°C to about 15°C thereby causing the gelatin to gel or solidify into microcapsules. Once microcapules are produced, they are hardened to provide a durable particle.
- a crosslinking agent is introduced into the emulsion which reacts with the gelatin.
- the crosslinking agent is an aldehyde or inorganic salt.
- the aldehyde crosslinking agent is formaldehyde and preferably glutaraldehyde.
- Typical inorganic salts are poylphosphates. The hardened microcapsules are then removed from the emulsion by typical means such as filtration.
- microcapsules In accordance with this invention a wide range of microcapsules can be produced depending upon the condition employed in the process. Microcapsules having a small microencapsulation such as less than 20 microns are highly useful in the carbonless copy paper systems. However, microcapsules in the range of from 100 to 400 microns are provided in accordance with this invention.
- the above disclosure generally describes the invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for the purposes of illustration only and are not to limit the scope of the invention. In the following examples, percent means percent by weight unless otherwise indicated.
- a second yield of microcapsules was obtained upon further settling of the mixture providing about 12.4 g of greater than 300 micron microcapsules.
- Example II The procedure of Example I was repeated except that 15 ml of sodium polyaspartate diluted to 50 ml with water was added and 180 ml of additional water was added to the emulsion. A photo micrograph at 100X magnification of a portion of these microcapsules appears in Fig. 2.
- Example III As a comparison, the procedure of Example I was repeated with the exception that 110 ml of water and 20 ml of a 5% solution of a sodium polymetaphosphate (Graham's salt) sold under the trade name "Calgon" was substituted in place of the sodium polyaspartate. The product was passed through a course sieve on which 36.9 g of microcapsules was retained and 58.8 g of microcapsules passed through. A sieve analysis of the microcapsules which passed through the course screen was further sieve analyzed and the results appear in Table II below.
- a sodium polymetaphosphate GABA
- Example II The procedure of Example I was repeated with the exception that the emulsion droplets were in the range of from 5-10 microns and the crosslinking step was allowed to proceede for 24 hrs at 8.4°C. A dry powder comprising microcapsules was obtained which was sieve for particle size as shown in Table III below.
- Example V A series of runs were made employing 120 ml of 8.33% aqueous solution of 160 Bloom Type A Gelatin. No foam suppressant was employed in these runs. The general procedure of Example I was repeated in each run except that in Example VA, 80 ml of Rose Oil was emulsified, in Example VB, Lilac Oil was emulsified and in Example VC Balsam Fir Oil was emulsified. In each run 10 ml of a 28% aqueous solution of sodium polyaspartate (Avg. Mol. Wt. 9200) diluted in 40 ml of water was added together with 170 ml of additional distilled water.
- sodium polyaspartate Avg. Mol. Wt. 9200
- the pH of the emulsion was lowered to about 4.4 with glacial acetic acid and the temperature of the emulsion held at about 48°C to 49°C.
- the acidified emulsion was then cooled to a range of from 9.5°C to about 10°C overnight in an ice bath.
- the microcapsules were crosslinked by introducing 5 ml of 25% glutaraldehyde.
- the crosslinking reaction proceeded for 24 hrs. at room temperature to provide, after filtration, a dry powder of microcapsules. None of the microcapsules in each run leaked as evidenced by the lack of any odor from the encapsulated oils.
- Crosslinking reaction proceeded for 24 hrs. at room temperature. After separation and drying, a free flowing powder of microcapsules was produced.
- Example VII Duplicate runs were made to microencapsulate a herbicide. The general procedure of Example I was followed in each case except that in Example VIIB, 231 Bloom Type A Gelatin was employed. In each run 30 g of a commerically prepared herbicide sold under the trade name Triallate Tech. by Monsanto Company, St. Louis, Mo. was emulsified in the gelatin solution. In Example VIIA 140 ml of water was added to the emulsion in the coacervation step while in Example VIIB 180 ml of water was added. After cross linking with gluteraldeyde, the microcapsules were dried. The microcapsules were analyzed for particle size and the results appear in Table IV below.
- Example VIII The procedure of Example I was repeated with the exception that 231 Bloom Type A Gelatin was employed in place of 200 Bloom Type A Gelatin and only 30 ml of dibutylphthalate was employed in place of 80 ml. Sieve analysis of the dried microcapsules appears in Table V below.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69602933T DE69602933T2 (en) | 1995-04-12 | 1996-03-19 | METHOD FOR MICRO-ENCLOSURE |
AU52560/96A AU5256096A (en) | 1995-04-12 | 1996-03-19 | Microencapsulation process |
JP8531011A JPH11503960A (en) | 1995-04-12 | 1996-03-19 | Microencapsulation method |
EP96908859A EP0820346B1 (en) | 1995-04-12 | 1996-03-19 | Microencapsulation process |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/420,463 US5540927A (en) | 1995-04-12 | 1995-04-12 | Microencapsulation process by coacervation |
US08/420,463 | 1995-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996032191A1 true WO1996032191A1 (en) | 1996-10-17 |
Family
ID=23666586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/003731 WO1996032191A1 (en) | 1995-04-12 | 1996-03-19 | Microencapsulation process |
Country Status (7)
Country | Link |
---|---|
US (1) | US5540927A (en) |
EP (1) | EP0820346B1 (en) |
JP (1) | JPH11503960A (en) |
AT (1) | ATE181254T1 (en) |
AU (1) | AU5256096A (en) |
DE (1) | DE69602933T2 (en) |
WO (1) | WO1996032191A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646133A (en) * | 1996-03-14 | 1997-07-08 | Donlar Corporation | Polyaspartic acid and its analogues in combination with insecticides |
KR100541753B1 (en) * | 1999-07-27 | 2006-01-10 | 가부시키가이샤 시세이도 | Microcapsule and a process for its preparation |
US6492025B1 (en) | 2000-11-27 | 2002-12-10 | Xerox Corporation | Microcapsule composition |
US6488870B1 (en) | 2000-11-27 | 2002-12-03 | Xerox Corporation | Encapsulation process |
FR2824756B1 (en) * | 2001-05-16 | 2005-07-08 | Mainelab | MICROCAPSULES BASED ON PLANT PROTEINS |
DE10157046A1 (en) * | 2001-11-18 | 2003-06-12 | Novosom Ag | Nano and microcapsules comprising reactive polymers |
US7202006B2 (en) | 2005-06-20 | 2007-04-10 | Xerox Corporation | Protective layer for reimageable medium |
CN101252845B (en) * | 2005-08-30 | 2012-03-28 | 弗门尼舍有限公司 | Encapsulated active ingredients, methods of preparation and their use |
JP2007223907A (en) | 2006-02-21 | 2007-09-06 | Sumika Enviro-Science Co Ltd | Microcapsule formulation and method for producing the same |
US20080277596A1 (en) * | 2007-05-08 | 2008-11-13 | Southwest Research Institute | Impact Indicating Microcapsules |
ES2383271B1 (en) * | 2010-03-24 | 2013-08-01 | Lipotec S.A. | PROCESSING PROCESSING OF FIBERS AND / OR TEXTILE MATERIALS |
ES2856080T3 (en) | 2014-03-28 | 2021-09-27 | Nusil Tech Llc | Dispersions containing encapsulated materials and compositions using the same |
TWI673103B (en) * | 2018-10-19 | 2019-10-01 | 國立清華大學 | Injectable self-assembling microbead-gel, use thereof, and method for preparing injectable self-assembling microbead-gel |
CN110353240A (en) * | 2019-07-11 | 2019-10-22 | 东莞市华井生物科技有限公司 | Essence microcapsule and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2145992A (en) * | 1983-09-01 | 1985-04-11 | Damon Biotech Inc | Microencapsulation of viable cells |
WO1993024076A1 (en) * | 1992-05-29 | 1993-12-09 | The Regents Of The University Of California | Coated transplant and method for making same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800457A (en) * | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
US4803168A (en) * | 1983-09-01 | 1989-02-07 | Damon Biotech, Inc. | Microencapsulation with polymers |
EP0179023B1 (en) * | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | With micro-organisms degradable polypeptide, and its use for the progressive release of medicaments |
US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
DE3921912A1 (en) * | 1989-07-04 | 1991-01-17 | Roehm Gmbh | POLYASPARAGINE ACID DERIVATIVES AS A COATING AGENT FOR MEDICINAL FORMS AND FOOD |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
-
1995
- 1995-04-12 US US08/420,463 patent/US5540927A/en not_active Expired - Fee Related
-
1996
- 1996-03-19 WO PCT/US1996/003731 patent/WO1996032191A1/en active IP Right Grant
- 1996-03-19 DE DE69602933T patent/DE69602933T2/en not_active Expired - Fee Related
- 1996-03-19 AT AT96908859T patent/ATE181254T1/en not_active IP Right Cessation
- 1996-03-19 EP EP96908859A patent/EP0820346B1/en not_active Expired - Lifetime
- 1996-03-19 JP JP8531011A patent/JPH11503960A/en active Pending
- 1996-03-19 AU AU52560/96A patent/AU5256096A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2145992A (en) * | 1983-09-01 | 1985-04-11 | Damon Biotech Inc | Microencapsulation of viable cells |
WO1993024076A1 (en) * | 1992-05-29 | 1993-12-09 | The Regents Of The University Of California | Coated transplant and method for making same |
Also Published As
Publication number | Publication date |
---|---|
AU5256096A (en) | 1996-10-30 |
DE69602933D1 (en) | 1999-07-22 |
ATE181254T1 (en) | 1999-07-15 |
EP0820346A1 (en) | 1998-01-28 |
US5540927A (en) | 1996-07-30 |
JPH11503960A (en) | 1999-04-06 |
DE69602933T2 (en) | 2000-01-20 |
EP0820346B1 (en) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5540927A (en) | Microencapsulation process by coacervation | |
Risch | Encapsulation: overview of uses and techniques | |
Jyothi et al. | Microencapsulation techniques, factors influencing encapsulation efficiency | |
Arshady | Microspheres and microcapsules: A survey of manufacturing techniques. Part 1: Suspension cross‐linking | |
US5023024A (en) | Process for producing microcapsules | |
US4025455A (en) | Cross-linked hydroxypropylcellulose microcapsules and process for making | |
JP2866385B2 (en) | Preparation of multi-wall polymer microcapsules | |
US4402856A (en) | Microcapsules with a defined opening temperature, a process for their production and their use | |
JPH0568300B2 (en) | ||
CA2073685A1 (en) | Aqueous core microcapsules and method for their preparation | |
JP2001504452A (en) | Process for the preparation of microcapsules coated with an active substance with a polymer and in particular novel microcapsules obtained by this process | |
Andrianov et al. | Controlled release using ionotropic polyphosphazene hydrogels | |
AU4602797A (en) | Microencapsulation process using supercritical fluids | |
JPS63197540A (en) | Gelatin-polysaccharide micro-capsule and manufacture thereof | |
US5169632A (en) | Microcapsules from polyfunctional aziridines | |
Tarun et al. | Patented microencapsulation techniques and its application | |
Sparks et al. | Selection of coating and microencapsulation processes | |
JPS63178840A (en) | Slowly-releasable microcapsule | |
Ayyaril et al. | Recent progress in micro and nano-encapsulation techniques for environmental applications: A review | |
JP2851302B2 (en) | Manufacturing method of microcapsules containing water-soluble substance | |
Nixon | Preparation of microcapsules with possible pharmaceutical use | |
Lamprecht et al. | Microencapsulation | |
CA2352802C (en) | Preparation of multiwall polymeric microcapsules from hydrophilic polymers | |
JPH069650B2 (en) | Method for producing sustained-release microcapsules | |
Belali et al. | Solvent Evaporation as an Efficient Microencapsulating Technique for Taste Masking in Fast Disintegrating Oral Tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996908859 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1996 531011 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996908859 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996908859 Country of ref document: EP |